<DOC>
	<DOCNO>NCT00849485</DOCNO>
	<brief_summary>The objective study compare rate extent absorption test formulation Levetiracetam tablets versus reference KeppraÂ® administer 1 x 750 mg tablet feed condition .</brief_summary>
	<brief_title>Levetiracetam 750 mg Tablets Under Non-Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Inclusion Criteria Male Female , smoker nonsmoker , age 18 year 55 year . BMI great equal 19.0 less 30.0 kg/m2 . Exclusion Criteria Subjects follow applies exclude study : Clinically significant illness surgery within 4 week administration study medication . Any clinically significant abnormality abnormal laboratory test result find medical screening . Any reason , opinion medical subinvestigator , would prevent subject participate study . Positive test hepatitis B , hepatitis C HIV screen . ECG abnormality ( clinically significant ) vital sign abnormality ( systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 50 90 ; heart rate le 50 bpm 100 bpm ) screening . History significant alcohol abuse drug abuse within one year prior screen visit . Regular use alcohol within six month prior screen visit ( fourteen unit alcohol per week [ 1 Unit = 150 mL wine , 360 mL beer 45 mL 40 % alcohol ] ) , positive alcohol breath test screening . Use soft drug ( marijuana ) within 3 month screen visit hard drug ( cocaine , phencyclidine ( PCP ) crack ) within 1 year screen visit positive urine drug screen screen . History allergic reaction heparin , levetiracetam , related drug . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , omeprazole ; examples inhibitor : antidepressant , cimetidine , diltiazem , macrolides , imidazole , neuroleptic , verapamil , fluoroquinolones , antihistamine ) within 30 day prior administration study medication . Use investigational drug participation investigational study within 30 day prior dose . Clinically significant history presence gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g . diarrhea , vomit ) , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug . Any clinically significant history presence neurological , endocrinal , cardiovascular , pulmonary , hematologic , immunologic , psychiatric metabolic disease . Use prescription medication within 14 day prior administration study medication overthecounter product ) include natural food supplement , vitamin , garlic supplement ) within 7 day prior administration study medication , except topical product without systemic absorption . Difficulty swallow study medication . Smoking 25 cigarette per day . Any food allergy , intolerance , restriction , special diet , , opinion Medical SubInvestigator could contraindicate subject 's participation study . A depot injection implant drug within 6 month prior administration study medication . Donation plasma ( 500 mL ) within 30 day prior drug administration . Donation loss whole blood ( exclude volume blood drawn screening procedure study ) prior administration study medication follow : 50 mL 500 mL whole blood within 30 day 500 mL whole blood within 56 days.+ Difficulty fast consume standard meal . Intolerance venipuncture . Clinically significant history renal , hepatic , cardiovascular disease , tuberculosis , epilepsy , asthma , diabetes , psychosis glaucoma eligible study . Positive urine pregnancy test screening . Breast feeding subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>